Foresite Capital Management V, LLC bought $2.5M of Latigo Biotherapeutics (LTGO)
Executed Aug 10, disclosed Aug 11, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 10), the stock returned +31.1% (delay-adjusted); from the execution session (Aug 10), +31.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Foresite Capital Management V, LLC (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Latigo Biotherapeutics, Inc. (LTGO). Across 1 priced purchase filing, the average 21-session return was +31.1% from execution and +31.1% from disclosure (delay-adjusted; derived). The largest single filing was $2.5M of LTGO (140,000 sh × $18.00, as filed), executed Aug 10.
Healthcare · Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→